Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications (Q34754695)

4 August 2017

1 reference

title

Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications (English)

1 reference

4 August 2017

1 reference

Shaker A Mousa

1

1 reference

4 August 2017

1 August 2002

1 reference

Current Opinion in Chemical Biology

4 August 2017

1 reference

4 August 2017

6

1 reference

4 August 2017

4

1 reference

4 August 2017

534-541

1 reference

Arg-Gly-Asp: a versatile cell recognition signal

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Integrins: versatility, modulation, and signaling in cell adhesion

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

The pharmacology of the integrins

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

A link between cyclin A expression and adhesion-dependent cell cycle progression

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Signal transduction from the extracellular matrix

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Signal transduction by integrins: increased protein tyrosine phosphorylation caused by clustering of beta 1 integrins

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Signal transduction by the platelet integrin alpha IIb beta 3: induction of calcium oscillations required for protein-tyrosine phosphorylation and ligand-induced spreading of stably transfected cells

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Antiplatelet therapies: from aspirin to GPIIb/IIIa-receptor antagonists and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Pulmonary eosinophilia in a murine model of allergic inflammation is attenuated by small molecule alpha4beta1 antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Migration of multiple sclerosis lymphocytes through brain endothelium.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

The adhesion molecule and cytokine profile of multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Fibronectin: structure, assembly, and cardiovascular implications

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Blood vessel fibronectin increases in conjunction with endothelial cell proliferation and capillary ingrowth during wound healing

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

A nonpeptide integrin antagonist can inhibit epithelial cell ingestion of Streptococcus pyogenes by blocking formation of integrin alpha 5beta 1-fibronectin-M1 protein complexes

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Long-term administration of glycoprotein IIb/IIIa antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin alpha v beta 3 and osteopontin expression during n

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Requirement of vascular integrin alpha v beta 3 for angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Beta3 integrin expression in melanoma predicts subsequent metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

The role of the integrin vitronectin receptor, alpha v beta 3 in melanoma metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Integrins in invasive growth

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Definition of Two Angiogenic Pathways by Distinct alpha(v) Integrins

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

The osteoclast functional antigen, implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

ArgGlyAsp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts*1

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Discovery of potent nonpeptide vitronectin receptor (alpha v beta 3) antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Alphavbeta3 integrin binding affinity and specificity of SM256 in various species

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900350-2

7 January 2021

10.1016/S1367-5931(02)00350-2

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

12133730